Prime Medicine Inc Share Price

High:loading Low:loading Return: loading

Max:loading Min:loading Median:loading

Max:loading Min:loading Median:loading

loading...
loading...
loading...
loading...

Stock Range

Today’s Range
Low: 4.06 High: 4.24
52 Week Range
Low: 3.28 High: 9.86
Liquidityliquidity Low
Low Moderate High

Fundamentals

  • Market capMarket cap information

    $502 Mln

  • P/E RatioP/E Ratio information

    --

  • P/B RatioP/B Ratio information

    2.55

  • Industry P/EIndustry P/E information

    --

  • Debt to EquityDebt to Equity information

    0

  • ROEROE information

    -1 %

  • ROCEROCE information

    335.44 %

  • Div. YieldDiv. Yield information

    0 %

  • Book ValueBook Value information

    --

  • EPSEPS information

    -2128446

10 Years Aggregate

CFO

$-338.20 Mln

EBITDA

$-392.50 Mln

Net Profit

$-491.26 Mln

Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Prime Medicine
-53.72 16.81 -9.29 -47.16 -- -- --
BSE Sensex*
10.05 -1.91 0.04 22.42 9.79 14.35 11.05
S&P Small-Cap 600#
-5.82 -5.34 -13.73 -6.30 5.30 2.98 5.53
As on 07-Nov-2024  |  *As on 08-Nov-2024  |  #As on 26-Oct-2023
2023
Prime Medicine
-52.31
S&P Small-Cap 600
13.89
BSE Sensex
18.74

Essential Checks View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials Detailed View

loading...

*All values are in ($ Mln)

loading...

*All values are in ($ Mln)

loading...

*All values are in ($ Mln)

Key Ratios view all

loading...

loading...

loading...

3Y Avg -- 5Y Avg -- TTM --

loading...
P/E Ratio

--

--Min --Median --Max

loading...
P/B Ratio

--

--Min --Median --Max

loading...
Earnings Yield (%)

--

Earnings Yield (%) = EBIT / Enterprise value

PEG Ratio

--

Price = Price / Earnings to growth ratio

loading...

loading...

loading...

Peer view all

Company
Price ($) Market Cap ($ Mln) P/E Ratio ROE
2.67 224.56 -- -1695.99
7.52 494.99 -- -72.84
8.31 563.53 -- -8.05
20.80 502.78 -- -13.06

Shareholding Pattern Detailed Holdings

loading...

About The Company More Details

President, CEO, Secretary & Director

Dr. Keith Michael Gottesdiener Ph.D.

President, CEO, Secretary & Director

Dr. Keith Michael Gottesdiener M.D., Ph.D.

Headquarters

Cambridge, MA
Edit peer-selector-edit
loading...
loading...

Key Facts

  • Market cap market-cap-information $501.73 Mln
  • Revenue (TTM)revenue-information $65.60 Mln
  • Earnings (TTM) earning-information $0.00 Mln
  • Cash date-information $162.87 Mln
  • Total Debt info $41.58 Mln
  • Insider's Holding 26.12%
  • Liquidity liquidity Low
  • 52 Week range week-range $3.28 - 9.86
  • Shares outstanding share-outstanding 120,031,000
  • 5 Years Aggregate:

    CFO: $-338.20 Mln

    EBITDA: $-392.50 Mln

    Net Profit: $-491.26 Mln

About The Company

  • IPO Date 20-Oct-2022
  • President, CEO, Secretary & Director Dr. Keith Michael Gottesdiener Ph.D.
  • President, CEO, Secretary & Director Dr. Keith Michael Gottesdiener M.D., Ph.D.
  • Listing key-listing NASDAQ: PRME
  • Country United States
  • Headquarters headquarters Cambridge, MA
  • Website website https://primemedicine.com
  • Business

    Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas...  protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company has a strategic research collaboration and license agreement with bristol myers squibb to develop and commercialize multiple prime edited ex vivo t-cell therapies. Prime Medicine, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts. Address: 21 Erie Street, Cambridge, MA, United States, 02139  Read more

FAQs for Prime Medicine Inc

The total asset value of Prime Medicine Inc stood at $ 280 Mln as on 30-Jun-24

The share price of Prime Medicine Inc is $4.10 (NASDAQ) as of 07-Nov-2024 16:00 EST. Prime Medicine Inc has given a return of -47.16% in the last 1 years.

Prime Medicine Inc has a market capitalisation of $ 502 Mln as on 06-Nov-2024. As per Value Research classification, it is a Small Cap company.

The P/B ratio of Prime Medicine Inc is 2.55 times as on 06-Nov-2024, a 3% discount to its peers’ median range of 2.63 times.

Since, TTM earnings of Prime Medicine Inc is negative, P/E ratio is not available.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Prime Medicine Inc and enter the required number of quantities and click on buy to purchase the shares of Prime Medicine Inc.

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company has a strategic research collaboration and license agreement with bristol myers squibb to develop and commercialize multiple prime edited ex vivo t-cell therapies. Prime Medicine, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts. Address: 21 Erie Street, Cambridge, MA, United States, 02139

The CEO & director of Dr. Keith Michael Gottesdiener Ph.D.. is Prime Medicine Inc, and CFO & Sr. VP is Dr. Keith Michael Gottesdiener M.D., Ph.D..

There is no promoter pledging in Prime Medicine Inc.

Prime Medicine Inc Ratios
Return on equity(%)
-131.92
Operating margin(%)
-296.99
Net Margin(%)
-331.49
Dividend yield(%)
--

No, TTM profit after tax of Prime Medicine Inc was $0 Mln.